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Background: Abiraterone and cabazitaxel improve survival in patients with metastatic castration-resistant prostate cancer
(mCRPC). We conducted an open-label phase I/II trial of cabazitaxel plus abiraterone to assess the antitumor activity and toler-
ability in patients with progressive mCRPC after docetaxel (phase I), and after docetaxel and abiraterone (phase II)
(NCT01511536).
Patients and methods: The primary objectives were to determine the maximum tolerated dose (MTD) and dose-limiting
toxicities (DLTs) of cabazitaxel plus abiraterone (phase I), and the prostate-specific antigen (PSA) response defined as a 50%
decrease confirmed3 weeks later with this combination (phase II).
Results: Ten patients were enrolled in the phase I component; nine were evaluable. No DLTs were identified. The MTD was
established as the approved doses for both drugs (cabazitaxel 25mg/m2 every 3 weeks and abiraterone 1000mg once daily).
Daily abiraterone treatment did not impact on cabazitaxel clearance. Twenty-seven patients received cabazitaxel plus abirater-
one plus prednisone (5mg twice daily) in phase II. The median number of cycles administered (cabazitaxel) was seven (range:
1–28). Grade 3–4 treatment-emergent adverse events included asthenia (in 5 patients; 14%), neutropenia (in 5 patients; 14%)
and diarrhea (in 3 patients; 8%). Nine patients (24%) required dose reductions of cabazitaxel. Of 26 evaluable patients, 12
achieved a PSA response [46%; 95% confidence interval (CI): 26.6–66.6%]. Median PSA-progression-free survival was 6.9 months
(95% CI: 4.1–10.3 months). Of 14 patients with measurable disease at baseline, 3 (21%) achieved a partial response per re-
sponse evaluation criteria in solid tumors.
Conclusions: The combination of cabazitaxel and abiraterone has a manageable safety profile and shows antitumor activity
in patients previously treated with docetaxel and abiraterone.
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Introduction
Therapeutic options for men with metastatic castration-resistant
prostate cancer (mCRPC) have evolved considerably with the ap-
proval of five therapies associated with improved overall survival
(OS): cabazitaxel (taxane chemotherapy), abiraterone and enza-
lutamide [androgen receptor (AR)-targeted therapies], radium
223 (bone-targeted), and sipuleucel-T (immunotherapy) [1].
These new treatments have improved OS in patients with
mCRPC, but there is a need to provide robust evidence on how
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these agents should be used, in sequence or combination, to
achieve optimal medical management [2, 3].
Cabazitaxel is a second-generation taxane indicated for the
treatment of patients with mCRPC pretreated with castration
and docetaxel [4]. Phase I and II clinical studies have shown that
neutropenia is the primary dose-limiting toxicity (DLT) [5, 6].
The recommended cabazitaxel dose was established as 25 mg/m2
administered intravenously once every 3 weeks. A phase III
randomized trial comparing cabazitaxel plus prednisone with
mitoxantrone (TROPIC) found that cabazitaxel improved
progression-free survival (PFS) and OS in patients with mCRPC
who have progressed on prior docetaxel treatment [4].
Abiraterone is an inhibitor of CYP17, an enzyme required for an-
drogen biosynthesis [7]. Two phase III randomized trials com-
paring abiraterone plus prednisone against prednisone alone
in patients with mCRPC found that abiraterone significantly
increased radiographic PFS and OS [8, 9]. Following these pivotal
trials, cabazitaxel 25 mg/m2 administered intravenously once
every 3 weeks, and abiraterone 1000 mg administered once daily,
were approved for use in patients with mCRPC who had previ-
ously received docetaxel.
An important potential therapeutic approach to be explored is
the combined use of taxane-based chemotherapy and AR-
targeted therapy, given their partially overlapping mechanisms of
action and toxicities [10]. We hypothesized that the combination
of an AR-targeted therapy and chemotherapy can maximize anti-
tumor activity in patients with mCRPC previously treated with
docetaxel.
Here we report the results of phase I/II trial (NCT01511536) of
cabazitaxel plus abiraterone in patients with mCRPC who had
previously received docetaxel and abiraterone. A dose escalation
phase I study was conducted to determine the maximum toler-
ated dose (MTD) and DLTs of cabazitaxel-abiraterone combin-
ation. An expansion phase II study investigated the activity of
cabazitaxel-abiraterone combination in terms of prostate-
specific antigen (PSA) response rate. Secondary objectives
included safety, pharmacokinetic (PK) profile, and assessment of
the preliminary antitumor activity in terms of PFS, OS, and re-
sponse rate.
Patients and methods
Patient population
The study enrolled patients aged 18 years with histologically or cyto-
logically confirmed mCRPC, previously treated with a docetaxel-
containing regimen. Patients had documented progressive disease,
and an Eastern Cooperative Oncology Group performance status of
0–1. All patients had progressive disease documented by rising PSA.
In phase I, in addition to rising PSA, progressive disease must have
been documented by an increase in non-measurable/measurable disease
and/or the appearance of new lesions. In phase II, enrolled patients
had progressive disease documented by rising PSA only, and
had received abiraterone for 3 months, which they were continuing to
receive before study entry (full eligibility criteria in supplementary
Table S1, available at Annals of Oncology online). The study
was approved by the institutional review board at each study center and
was conducted in compliance with guidelines for Good Clinical
Practice. Patients provided written informed consent before study
participation.
Study design and treatment
This was a phase I/II, multicenter, open-label, dose escalation, and dose ex-
pansion study of cabazitaxel plus abiraterone and prednisone in patients
with mCRPC previously treated with docetaxel. In the phase I part of the
study, cohorts of three to six patients received one of two cabazitaxel dose
levels (20 or 25 mg/m2) by 1-h intravenous infusion on day 1 of each 3-
weekly cycle, according to a standard 3þ 3 dose escalation design. The rec-
ommended dose of cabazitaxel was determined as 20 and 25 mg/m2 in early
phase I studies [5, 6]; therefore both doses were assessed in combination
with abiraterone. All patients also received oral abiraterone 1000 mg once
daily in fasting conditions and oral prednisone 5 mg twice daily. DLTs dur-
ing Cycles 1 and 2 in phase I were defined according to the National Cancer
Institute Common Terminology Criteria for Adverse Events (AE) [11] as
grade 3–4 non-hematologic AE, or hematologic toxicity defined as febrile
neutropenia (fever 38.5 C of unknown origin, without infection, with
grade 3–4 neutropenia), grade 4 neutropenia lasting> 7 days, grade 4
thrombocytopenia or grade 3 thrombocytopenia complicated by hemor-
rhage. Treatment delay of> 2 weeks due to delayed recovery was con-
sidered a DLT. Prophylactic use of granulocyte-colony stimulating factor
(G-CSF) was not permitted during Cycle 1, but allowed in subsequent
cycles in the case of neutropenia-related DLTs (for details, see supplemen
tary information, available at Annals of Oncology online). The phase II part
of the study was an open-label, multicenter study to evaluate safety and tol-
erability and to assess the activity of cabazitaxel plus abiraterone at the
MTD determined in phase I. Treatment was not limited to a certain num-
ber of cycles and continued until disease progression, unacceptable toxicity,
investigator’s decision, or withdrawal of consent. Radiologic disease pro-
gression was defined according to Response Evaluation Criteria In Solid
Tumors (RECIST 1.1.) [12].
PK assessments
For cabazitaxel PK parameters, blood samples were collected from all pa-
tients at predetermined time points during the phase I and phase II parts
of the study. Further details are available in the supplementary informa
tion, available at Annals of Oncology online.
Efficacy assessments
The primary endpoint of the phase II part of the study was PSA response
rate, defined as a decline of serum PSA from baseline of 50% confirmed
at least
3 weeks later. PSA was assessed at baseline and every 3 weeks during
study treatment. Tumor assessments by computed tomography scan and
bone scan were performed at baseline and every 12 weeks thereafter.
Tumor response was evaluated according to RECIST 1.1. [12].
Statistical considerations
In prior studies, the PSA response rate was 29% (N¼ 797) in patients
with mCRPC who received abiraterone post-docetaxel [8], and 39%
(N¼ 329) in patients who received cabazitaxel post-docetaxel [4, 8].
Therefore, in this study for patients receiving abiraterone plus cabazitaxel
post-docetaxel, the null hypothesis was set as a 25% PSA response rate,
versus an alternative hypothesis of a 50% PSA response rate (an absolute
difference of 25%); to reject the null hypothesis, a cohort of 26 patients
would have approximately 83% power with a type I error rate of 5%,
using a one-sided exact binomial test.
Results
Patient characteristics and study drug exposure
Overall, a total of 37 patients with mCRPC were enrolled onto
the study; 10 onto the dose escalation phase I and 27 onto the
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dose expansion phase II components, between 28 March 2012
and 18 June 2014 at 4 centers. All patients received at least one
cycle of cabazitaxel plus abiraterone. Baseline demographics and
disease characteristics are shown in supplementary Table S2,
available at Annals of Oncology online. In the phase I part of the
study, patients with progressive mCRPC after docetaxel treat-
ment were enrolled. In the phase II part of the study all patients
had progressed on docetaxel, received at least 3 months of abira-
terone, and continued treatment with abiraterone, prior to study
entry.
Patients and safety
In the phase I dose escalation part of the study, 9 out of 10 pa-
tients were evaluable for DLTs. Three patients receiving cabazi-
taxel 20 mg/m2 and six patients receiving cabazitaxel 25 mg/m2
completed two treatment cycles without experiencing any DLTs.
The MTD of the combination was established as the full and
approved dose of both agents (cabazitaxel 25 mg/m2 once every 3
weeks and abiraterone 1000 mg once daily). The median number
of cabazitaxel plus abiraterone treatment cycles administered per
patient was six (range 4–20).
In phase II (expansion), 27 patients received cabazitaxel
(25 mg/m2 every 3 weeks) in combination with continuous abira-
terone (1000 mg once daily). The median number of treatment
cycles administered per patient was 7 (range 1–28) and 8 (1–28)
for cabazitaxel and abiraterone, respectively. Eight patients
(30%) required a reduction of the cabazitaxel dose and three pa-
tients (11%) required a reduction of the abiraterone dose (supple
mentary Table S3, available at Annals of Oncology online) during
study treatment. In phase II of this study, 19 patients (70%)
received G-CSF after the first treatment cycle. Thirteen patients
(48%) discontinued the study due to an AE.
AEs were similar across the phase I and phase II parts of the
study. The most common treatment emergent AEs (TEAEs) pos-
sibly related to study treatment are listed in Table 1 (both phases)
and supplementary Table S4 (phase I), available at Annals of
Oncology online. The majority of treatment-related TEAEs were
grade 1–2 in severity. The most frequent all-grade treatment-
related TEAEs in the phase I part of the study were nausea (50%),
asthenia (40%), and diarrhea (40%). One patient presented with
grade 3 diarrhea, considered to be related to concurrent infection.
In the phase II part of the study, the most common all-grade
TEAEs possibly related to study treatment were asthenia (59%),
nausea (41%), and diarrhea (41%). The most common grade 3–4
AEs were hematologic toxicities; only one patient (3.7%) experi-
enced febrile neutropenia. The most common grade 3–4 hemato-
logic laboratory abnormalities were neutropenia (n¼ 15; 56%),
leukopenia (n¼ 14; 52%), and lymphopenia (n¼ 13; 48%). Six
patients died within 30 days of study treatment due to disease
progression (n¼ 2; 7%) and AEs (n¼ 4; 15%) including pneu-
monia, acute renal failure, septic shock, and acute coronary syn-
drome, all assessed as not related to study treatment
(supplementary information, available at Annals of Oncology on-
line). There were three additional deaths due to disease progres-
sion by the end of the study. Overall, AEs were similar to those
previously reported in the cabazitaxel phase III TROPIC trial and
the abiraterone phase III COU-AA-301 trial [4, 8].
Phase II expansion study: antitumor activity
Overall 26 patients were evaluable for assessment of antitumor
activity in the phase II part of the study; 12 achieved a PSA re-
sponse [46.2%; 95% confidence interval (CI): 26.6–66.6]; the null
hypothesis of a 25% PSA response rate was therefore rejected
(P< 0.01). The percentage of patients with a 30% PSA decrease
from baseline was 61.5% (16/26; 95% CI: 42.8–80.2) (Figure 1).
For the 14 patients evaluable for tumor response according to
RECIST 1.1. [12], the response rate was 21.4% (3/14; 95% CI:
4.7–50.8); an additional 7 patients (50.0%) had a best response of
stable disease (Table 2). Of the 12 patients demonstrating a PSA
response, 6 maintained the response for at least 6 months, and 1
maintained the response for over 12 months. The median dur-
ation of PSA response was 6.7 months (95% CI: 3.3–9.6 months).
The median PSA–PFS was 6.9 months (95% CI: 4.1–10.3
months). There was no statistically significant difference in PSA
response between patients who did or did not have a response
with prior docetaxel and abiraterone treatment (supplementary
Table S5, available at Annals of Oncology online).
Pharmacokinetics
PK data are presented in Table 3. Abiraterone mean maximum
concentration (Cmax) [221 ng/mL; coefficient of the variation (CV)
84%] and mean area under the concentration-time curve from 0 to
24 h (AUC0-24h) (872 ng*h/mL; CV 43%) observed in the phase I
and phase II parts of the study were in accordance with data re-
ported in the literature for abiraterone given as a single agent, indi-
cating that cabazitaxel did not affect abiraterone steady-state
exposure (supplementary Table S6, available at Annals of Oncology
Table 1. Patients experiencing possibly related TEAEs in 10% of patients
and laboratory abnormalities
Patients, n (%) Phase I (N 5 10) Phase II (N5 27)
TEAEs Grade  3 All grades Grade  3 All grades
Any possibly
related TEAE
3 (30.0) 10 (100) 12 (44.4) 27 (100)
Asthenia 1 (10.0) 4 (40.0) 4 (14.8) 16 (59.3)
Nausea 0 5 (50.0) 0 11 (40.7)
Diarrhea 1 (10.0) 4 (40.0) 2 (7.4) 11 (40.7)
Decreased appetite 0 2 (20.0) 1 (3.7) 9 (33.3)
Dyspnea 0 2 (20.0) 1 (3.7) 7 (25.9)
Neutropenia 0 0 5 (18.5) 5 (18.5)
Vomiting 0 0 1 (3.7) 5 (18.5)
Stomatitis 0 3 (30.0) 0 2 (7.4)
Hypokalemia 0 1 (10.0) 0 3 (11.1)
Dysgeusia 0 2 (20.0) 0 2 (7.4)
Fatigue 1 (10.0) 2 (20.0) 0 2 (7.4)
Laboratory abnormalities
Anemia 0 10 (100.0) 2 (7.4) 27 (100.0)
Leukopenia 3 (30.0) 9 (90.0) 14 (51.9) 23 (85.2)
Neutropenia 2 (20.0) 9 (90.0) 15 (55.6) 19 (70.4)
Lymphopenia 0 7 (70.0) 13 (48.1) 24 (88.9)
Thrombocytopenia 0 4 (40.0) 1 (3.7) 16 (59.3)
TEAEs, treatment-emergent AE.
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online). Cabazitaxel exposure after repeated daily oral administra-
tion of abiraterone (mean plasma clearance 26.1–31.4 across phase
I and phase II) was comparable to previous studies of cabazitaxel
monotherapy at 25 mg/m2 [13]. This suggests that daily abirater-
one treatment does not significantly alter cabazitaxel clearance.
Repeated abiraterone exposure observed when abiraterone
1000 mg/day was administered concomitantly with cabazitaxel at
20 or 25 mg/m2 (Cmax¼ 217 ng/mL and AUC0-24h¼ 916 ng*h/mL)
was consistent in both phases.
Discussion
Findings from this phase I/II study showed that in patients with
mCRPC who had previously received docetaxel, the administra-
tion of cabazitaxel in combination with abiraterone was generally
well tolerated when both agents were administered at the
approved doses. The tolerability profile was consistent with the
established safety profiles of cabazitaxel and abiraterone mono-
therapy [4, 8]. There was no evidence of a PK interaction between
cabazitaxel and abiraterone. The combination had clinically im-
portant antitumor activity. The rate of 50% PSA declines from
baseline [12 of 26 evaluable patients (46.2%)] and tolerability
supports the future evaluation of this combination. Of note, a re-
cent phase III PROSELICA trial demonstrated the non-
inferiority of cabazitaxel 20 mg/m2 versus 25 mg/m2 with respect
to OS [14]. In this trial, cabazitaxel 20 mg/m2 maintained at least
50% of the OS benefit previously observed for cabazitaxel 25 mg/
m2 versus mitoxantrone in the TROPIC trial [4], and may have
an improved safety profile [14]. These results should be con-
sidered in future trials of cabazitaxel combinations.
The overall safety profile of cabazitaxel plus abiraterone was
consistent with the safety profiles of each individual component.
The most frequent side effects were asthenia and neutropenia,
with one patient experiencing febrile neutropenia. The rate of fe-
brile neutropenia observed in the TROPIC trial was 8% for the
cabazitaxel plus prednisone treatment arm (n/N¼ 28/371) [4].
Proactive management of neutropenia may have reduced the risk
of febrile neutropenia in this study as most patients (70%)
received G-CSF after the first treatment cycle. The frequency of
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Figure 1. PSA response (phase II part of study, efﬁcacy population). (A) Duration of PSA
response: PSA–PFS in patients with an initial PSA response. (B) Maximal decline in PSA from
baseline. CI, conﬁdence interval; PSA, prostate-speciﬁc antigen.
Table 2. PSA response and tumor response (phase II)
Cabazitaxel
25mg/m21
abiraterone
1000mg/day
PSA response (N5 26), n (%)
PSA response 12 (46.2)
95% CI 26.6–66.6
P-valuea 0.006
Duration of PSA response (N ¼ 12)b
Number of patients progressed after
initial response, n (%)
8 (66.7)
Median duration of response in
months (95% CI)
6.7 (3.3–9.6)
Probability of maintaining
response at 3 months
0.825 (0.604–1.000)
Probability of maintaining
response at 5 months
0.589 (0.271–0.907)
PFS (N ¼ 26)c
Number of patients with progression (%) 11 (42.3)
Median PFS in months (95% CI) NC (4.7–NC)
Probability of PFS at 3 monthsd 0.762 (0.594–0.929)
Probability of PFS at 5 monthsd 0.677 (0.492–0.862)
Tumor response (N ¼ 14), n (%)c
Complete response 0
Partial response 3 (21.4)
Stable disease 7 (50.0)
Progressive disease 3 (21.4)
Not evaluable/missing data 1 (7.1)
ORR (N ¼ 14), n (%)
ORR 3 (21.4)
95% CI 4.7–50.8
aBased on the one-sided exact binomial test conducted on the null
hypothesis of a 25% response rate.
bSix patients in phase II received 10 or more cycles of cabazitaxel and
did not have PSA progression.
cEight patients completed 10 cycles of treatment and had not pro-
gressed by RECIST criteria at study completion.
dRefer to Kaplan–Meier curve (supplementary Figure S1, available at
Annals of Oncology online) for the interpretation of probability of PFS.
CI, conﬁdence interval; NC, not calculable; ORR, objective response
rate; PFS, progression-free survival; PSA, prostate-speciﬁc antigen.
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gastrointestinal toxicities in this study was similar to the rates re-
ported in the TROPIC trial for the cabazitaxel arm [4]; however,
these data should be interpreted with caution due to the small co-
hort size. The PK assessments and analysis in this study do
not provide evidence of any drug–drug interactions between cab-
azitaxel and abiraterone. Mean trough plasma concentrations
of cabazitaxel plus abiraterone were similar to those observed
in previous combination therapy and monotherapy studies
[15, 16].
In this population, cabazitaxel plus abiraterone combination
therapy demonstrated significant antitumor activity. A PSA re-
sponse was reported in 12 of 26 patients (46.2%), which is higher
than the PSA response rates observed in the phase III trials
of abiraterone (COU-AA-301) [8], and cabazitaxel in the
post-docetaxel setting (TROPIC) [4], where 29% and 39% of pa-
tients, respectively, demonstrated a 50% decline in PSA levels.
However, cross-trial comparisons should be interpreted with cau-
tion due to the broad CIs associated with these small cohorts.
Nonetheless, these phase II results are encouraging because the pa-
tient population differed from that of the TROPIC study, having
received a greater number of prior treatments. These results war-
rant further evaluation of cabazitaxel plus abiraterone in this popu-
lation of patients [17–19]. Several studies have retrospectively
investigated the efficacy of cabazitaxel as a third-line treatment after
docetaxel and abiraterone, and suggest that cabazitaxel remains ac-
tive after docetaxel and abiraterone treatment with declines of PSA
from baseline of 50% observed in 35–39% of patients [20, 21].
The response rate in our prospective phase II cabazitaxel and abira-
terone combination study indicates that this combination is at least
as active as cabazitaxel alone [4]. Randomized trials to ascertain the
optimal sequencing and/or combination of these and other novel
agents are urgently needed to maximize patient benefit, as is the
clinical qualification of predictive biomarkers of response including
AR-splice variant 7 expression, phosphatase, and tensin homolog
loss and broader genomic studies to deliver improved care for men
with mCRPC [22, 23].
Conclusions
In summary, cabazitaxel and abiraterone administered as a com-
bination treatment can be administered at the approved dose of
both monotherapies (25 mg/m2/1000 mg) with these being gen-
erally well tolerated. This combination had antitumor activity in
patients with mCRPC previously treated with docetaxel and abir-
aterone. The AE profile of this combination did not identify any
overlapping toxicities or present any new safety concerns.
Further studies are warranted to better define which patients with
mCRPC would benefit most from this combinational approach.
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